Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.

Escape Bio, a US-based biotherapeutics spinout of Gladstone Institutes targeting neurodegenerative diseases, raised $73m in crossover financing on Monday from investors including spinout-focused investment firm Osage University Partners (OUP). Pharmaceutical firms Novo, Johnson & Johnson and Novartis also participated, with the latter two investing through their respective subsidiaries Johnson & Johnson Innovation – JJDC and…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.